Can the art of predictive medicine anticipate the development of diabetes? And if so, what can be done about it? How early is early enough to intervene effectively? With what therapeutic modality? Why? Big babies are not an infrequent occurrence in mothers with normal carbohydrate metabolism for another 10, 20, or even 30 years. The abnor- mality present during pregnancy is now accepted as what is inherited with the diabetic predisposition, or what can be recognized as the diabetic susceptibility. It occurs before hyperglycemia, during the phase of dy- namic resistance to diabetes, during the prediabetic period. Prediabetes means before diabetes, and was applied for the first time by Mara~on in Spain, to signify the stage before hyperglycemia. Foglia in Argentina used the term in 1944 for his pancreatectomized rats. We pub- lished the first paper on humans in 1951 (Camerini-Davalos, R.A., Landabure, P., and Serantes, N., Rev Med Cordoba 39: 187).
Advances in Metabolic Disorders, Supplement 1: Early Diabetes covers the discussions during the first International Symposium on Early Diabetes. The book discusses the views of the role of genetic factors in diabetes; the genetic problem posed by the relatively high frequency of diabetes; the relationship between diabetes and prediabetes in the mother; and the congenital defect in the offspring. The text also describes the report on the genetics of diabetes among the Pima Indians, as well as the genetics of animals with spontaneous diabetes. The pathophysiology of diabetes mellitus, the concept of progression from prediabetes to chemical diabetes and then to overt diabetes, and the effect of aging on carbohydrate metabolism are also considered. The book further tackles the epidemiology of early diabetes, as well as the natural history of diabetes. The text concludes by looking into the treatment of early diabetes, including topics on insulin treatment of children with a late stage of chemical diabetes; complementary arguments in favor of the betacytotrophic action of the hypoglycemic sulphonamides; and the use of oral hypoglycemic compounds. Endocrinologists, biochemists, physiologists, and researchers working on the treatment of diabetes will find the book invaluable.
Advances in Metabolic Disorders, Supplement 2: Vascular and Neurological Changes in Early Diabetes covers knowledge of the vascular and neurological changes in early diabetes. The book discusses the prevalence of macroangiopathy in asymptomatic diabetes, the prevalence of asymptomatic diabetes in human atherosclerosis, and the observations made in seeking evidence for macroangiopathy, microangiopathy, and neurological changes in patients with latent diabetes. The text also describes angiopathy and neuropathy in mild juvenile diabetes; the role of insulin in the development of atherosclerosis; and the effect of insulin on lipid metabolism of human arteries. Discussions about microangiopathy, including topics on serum glycoprotein disturbances and their rheological effects in diabetes mellitus; the biochemical properties of human glomerular basement membrane in normal and diabetic kidneys; and the plasma levels of growth hormone and glucagon in diabetic patients and relatives of diabetic patients are also considered. The book further tackles topics about neuropathy, including the role of sorbitol pathway in neuropathy, the polyol pathway in the neuropathy of early diabetes, as well as nervous abnormalities in early diabetes. The text concludes by looking into the effect of treatment on diabetes. Endocrinologist, biochemists, physiologists, and researchers working on related topics will find the book useful.